Nasreen C. Jahed

发表

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

Chakra Budhathoki, David Katzenstein, James F. Rooney, 2011 .

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

P. Sax, E. Daar, D. Kitch, 2012, AIDS.

Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

D. Havlir, D. Margolis, K. Robertson, 2007, The Journal of infectious diseases.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

D. Katzenstein, K. Tashima, P. Sax, 2011, The Journal of infectious diseases.

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

D. Katzenstein, P. Sax, E. Daar, 2011, Annals of Internal Medicine.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102

D. Katzenstein, M. Winters, P. Tebas, 2006, Journal of acquired immune deficiency syndromes.

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

P. Sax, E. Daar, D. Kitch, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz : ACTG Study A 5224 s

P. Sax, E. Daar, D. Kitch, 2011 .

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density

P. Sax, E. Daar, D. Kitch, 2013, AIDS.